Vanguard Group Inc Minerva Neurosciences, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Minerva Neurosciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 252,060 shares of NERV stock, worth $441,105. This represents 0.0% of its overall portfolio holdings.
Number of Shares
252,060
Previous 252,060
-0.0%
Holding current value
$441,105
Previous $559,000
23.43%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding NERV
# of Institutions
19Shares Held
1.95MCall Options Held
0Put Options Held
0-
Federated Hermes, Inc. Pittsburgh, PA1.35MShares$2.36 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny114KShares$199,6690.0% of portfolio
-
Geode Capital Management, LLC Boston, MA76.7KShares$134,2810.0% of portfolio
-
Black Rock Inc. New York, NY72.7KShares$127,1700.0% of portfolio
-
Apella Capital, LLC20.6KShares$36,0930.0% of portfolio
About Minerva Neurosciences, Inc.
- Ticker NERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,340,190
- Market Cap $9.35M
- Description
- Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein ...